Tumor necrosis factor inhibitory polypeptide and application thereof

A technology of tumor necrosis factor and inhibitory peptide, applied in the field of medicine, can solve the problems of ineffective treatment, allergic reaction, neutralization, etc., and achieve the effect of preventing or treating rheumatoid arthritis

Inactive Publication Date: 2015-12-02
SUZHOU PULUODA BIOLOGICAL SCI & TECH
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Long-term injection treatment will cause allergic reactions on the one hand; on the other hand, a large number of antibodies will be produced in the patient's body, which will neutralize the effect of adalimumab, resulting in ineffective treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor necrosis factor inhibitory polypeptide and application thereof
  • Tumor necrosis factor inhibitory polypeptide and application thereof
  • Tumor necrosis factor inhibitory polypeptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Immunoprotective effect of tumor necrosis factor inhibitory polypeptide in collagen-induced mouse arthritis animal model

[0012] A collagen-type mouse arthritis animal model was constructed to study the therapeutic effect of tumor necrosis factor inhibitory polypeptide on collagen-induced arthritis (CIA) in mice. Using mice as experimental animals, 60 SPF grade DBA / 1 mice (provided by Sino-British SIPPRLab.AnimalLtd), animal production license number: SCXK (Shanghai) 2008- 0016), male, 7-8 weeks old, with a body weight of 18-22g, were randomly divided into 6 groups, which were normal control group, model control group, 3 dosage groups of low, medium and high polypeptide (0.4, 0.8, 1.6mg / kg) and Positive drug control group (methotrexate 2mg / kg). Except the normal group, mice CIA models were established in each experimental group on the 0th day by dissolving chicken cartilage type II collagen (cII) with 0.1 mol / l acetic acid into a 4 mg / ml solution and overnight in a re...

Embodiment 2

[0019] The immune protection effect of tumor necrosis factor inhibitory polypeptide on adjuvanted rat arthritis animal model in vivo

[0020] An animal model of adjuvant arthritis in rats was constructed to study the therapeutic effect of the polypeptide on Adjuvantarthritis (AA) rats. Rats were used as experimental animals, 60 SPF grade SD rats (provided by Shanghai SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai) 2008-0016) , male, body weight 140g-160g, were randomly divided into 6 groups, namely normal control group, model control group, 3 dose groups of low, medium and high tumor necrosis factor inhibitory polypeptide (0.2, 0.4, 0.8mg / kg) and positive drug control group (Methotrexate 1mg / kg). In addition to the normal group, on the 0th day, each experimental group established a rat AA model by injecting complete Freund's adjuvant containing inactivated Mycobacterium tuberculosis (H37RA, 10mg / ml) in the left rear of the rat. 0.1ml caused rat adjuv...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of drugs, particularly a polypeptide capable of inhibiting tumor necrosis factor and preventing and treating rheumatoid arthritis. The sequence is RINDISHTQSVSSKQKVTG and is a brand-new sequence. The polypeptide can be used for treating rheumatoid arthritis, and has potential new drug development value.

Description

Technical field: [0001] The invention relates to the field of medicines, in particular to tumor necrosis factor inhibitory polypeptides for preventing and treating or preventing rheumatoid arthritis. Background technique: [0002] Rheumatoid arthritis (rheumatoid arthritis, RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in our country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age of women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. RA is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, and belongs to autoimmune inflammatory disease. Patients often have hand or wrist pain and swelling (especially the swelling ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08A61K38/10A61P19/02A61P29/00
Inventor 罗瑞雪
Owner SUZHOU PULUODA BIOLOGICAL SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap